Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Net Margin of 1815.57% for Q1 2026, down 496.75% on a QoQ basis from 304.24% in Q4 2025, and down 44232.0% year-over-year from N/an in Q1 2025.
Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Net Margin history runs 7 years deep, the most recent figure standing at 1815.57% for Q1 2026.
- Quarterly Net Margin fell 44232.0% year-over-year to 1815.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 842.93% (up 11839.0% YoY) and the FY2025 annual result came in at 863.35%, down 7533.0% from the prior year.
- Net Margin was 1815.57% for Q1 2026 at Recursion Pharmaceuticals, down from 304.24% in the prior quarter.
- Across five years, Net Margin topped out at 304.24% in Q4 2025 and bottomed at 3935.46% in Q4 2024.
- A 5-year average of 1117.44% and a median of 853.88% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin sank 308158 bps — and 2025, when it jumped 363122 bps.
- Recursion Pharmaceuticals' Net Margin stood at 471.92% in 2022, then sank by 81 bps to 853.88% in 2023, then sank by 361 bps to 3935.46% in 2024, then soared by 92 bps to 304.24% in 2025, then plunged by 497 bps to 1815.57% in 2026.
- Business Quant data shows RXRX's Net Margin at 1815.57% in Q1 2026, 304.24% in Q4 2025, and 3135.32% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -1,815.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,815.57% |
| Dec 31, 2025 | -304.24% |
| Sep 30, 2025 | -3,135.32% |
| Jun 30, 2025 | -894.23% |
| Mar 31, 2025 | -1,373.26% |
| Dec 31, 2024 | -3,935.46% |
| Sep 30, 2024 | -367.46% |
| Jun 30, 2024 | -676.56% |
| Mar 31, 2024 | -662.41% |
| Dec 31, 2023 | -853.88% |
| Sep 30, 2023 | -883.10% |
| Jun 30, 2023 | -696.43% |
| Mar 31, 2023 | -538.38% |
| Dec 31, 2022 | -471.92% |
| Sep 30, 2022 | -475.58% |
| Jun 30, 2022 | -862.72% |
| Mar 31, 2022 | -1,049.97% |
| Dec 31, 2021 | -2,565.14% |
| Sep 30, 2021 | -1,839.86% |
| Jun 30, 2021 | -1,703.81% |